Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
TransMedics operates the Organ Care System (OCS), a portable perfusion platform that preserves donor organs (hearts, lungs, livers) in a near-physiologic state during transport, extending viable transplant windows beyond traditional cold storage. The company also provides National OCS Program (NOP) logistics services, managing end-to-end organ procurement and transport for transplant centers. With 82.7% revenue growth and expanding adoption across U.S. transplant centers, TMDX is capturing share in a market historically constrained by organ preservation technology limitations.
TransMedics generates revenue through a hybrid capital equipment and services model. Hospitals either purchase OCS consoles ($250K-$300K estimated) plus disposable perfusion sets ($30K-$40K per case), or contract for NOP services where TMDX owns the equipment and charges $80K-$120K per transplant case (estimated). NOP is higher-margin and recurring, driving the shift toward services revenue. Competitive advantage stems from FDA-approved technology that extends organ viability 6-12 hours beyond cold storage, enabling broader geographic procurement and increasing transplantable organ supply by 20-30% at adopting centers. The 59.4% gross margin reflects disposable set economics and NOP service pricing power, with limited direct competition in portable normothermic perfusion.
NOP case volume growth and penetration rates at contracted transplant centers - each incremental case drives high-margin recurring revenue
New transplant center contract signings for NOP services - expands addressable case volume and validates market adoption
Regulatory milestones and clinical data publications demonstrating superior organ utilization rates versus cold storage
Gross margin trajectory as NOP mix increases relative to capital equipment sales
International expansion progress, particularly European market entry where organ shortage is acute
Reimbursement risk - CMS or private payers could challenge incremental costs of OCS/NOP versus cold storage, though current transplant DRGs appear adequate to absorb technology costs
Clinical outcome scrutiny - any adverse events or studies questioning superiority versus cold storage could halt adoption momentum, particularly given the technology's premium pricing
Regulatory expansion risk - international approvals (Europe, Asia) face uncertain timelines and clinical trial requirements, delaying addressable market expansion
Emerging competition from ex-vivo perfusion technologies (XVIVO Perfusion AB in lungs, Paragonix cold storage solutions) could fragment market share
Large medtech incumbents (Medtronic, Abbott) could enter organ preservation via acquisition or internal development, leveraging hospital relationships
Alternative preservation technologies (hypothermic perfusion, preservation solutions) could offer lower-cost solutions that satisfy transplant centers' needs
Negative free cash flow of -$100M (estimated -1.7% FCF yield) requires continued equity or debt financing to fund NOP infrastructure expansion and working capital
High capex intensity ($100M annually) for NOP aviation assets, logistics hubs, and OCS console inventory strains cash generation during growth phase
1.46 debt/equity ratio manageable currently but could constrain flexibility if growth capital needs exceed cash generation and equity markets become unfavorable
low - Organ transplantation is non-discretionary medical care driven by clinical need rather than economic conditions. Hospital capital budgets for transplant programs are relatively insulated from GDP fluctuations given the life-saving nature and reimbursement stability. However, severe recessions could delay hospital capital equipment purchases, though NOP service model mitigates this risk by eliminating upfront hospital investment.
Rising interest rates create moderate headwinds through two channels: (1) higher cost of capital for hospital systems evaluating OCS console purchases, potentially accelerating NOP adoption but slowing direct equipment sales, and (2) valuation multiple compression for high-growth, unprofitable medtech stocks as investors demand higher risk premiums. The company's 1.46 debt/equity ratio suggests manageable financing cost exposure, but negative free cash flow makes equity financing costs relevant for growth capital.
Minimal direct credit exposure. Revenue is primarily from hospital systems with stable reimbursement (Medicare/Medicaid cover transplants) and commercial insurers. NOP contracts are typically multi-year with per-case billing, reducing payment risk. However, hospital financial stress could slow new contract signings or delay capital equipment purchases.
growth - The stock attracts growth investors focused on disruptive medtech with large addressable markets. The 82.7% revenue growth, 241.7% net income growth, and early-stage profitability appeal to investors willing to accept negative free cash flow for market share capture. The 80.6% one-year return and 8.2x price/sales ratio reflect growth premium valuation. Momentum investors also participate given strong recent performance, while the 31.4% ROE attracts GARP (growth at reasonable price) investors as profitability scales.
high - Small-cap medtech stocks with $4.6B market cap and binary clinical/regulatory catalysts exhibit elevated volatility. Limited analyst coverage and institutional ownership concentration amplify price swings on earnings surprises or clinical data releases. The stock's beta likely exceeds 1.5 given growth stage, negative free cash flow, and sector rotation sensitivity. Quarterly case volume misses or NOP contract signing delays can trigger 15-20% single-day moves.
